ImClone Systems Inc (formerly IMCL)

[biophud]

Jbog-sounds positive. I find it intersesting that IMCL is targeting untreated patients in the IGFR prostate trial--this is potentially a large market.

In contrast, in the VEGFR program for renal cell, IMCL is targeting patients who have failed prior therapy (including small molecule TKIs)--A smaller market but a potentially shorter path to aproval.

Regards,

biophud